Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Ann Hematol

Search In Journal Title:

Abbravation: Annals of Hematology

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1007/11949534_41

Search In DOI:

ISSN

1432-0584

Search In ISSN:
Search In Title Of Papers:

The novel compound OSI461 induces apoptosis and g

Authors: Raminder Singh Julia Fröbel RonPatrick Cadeddu Ingmar Bruns Thomas Schroeder Daniela Brünnert Christian Matthias Wilk Luiz Fernando Zerbini Rainer Haas Akos Czibere
Publish Date: 2011/06/30
Volume: 91, Issue: 2, Pages: 173-181
PDF Link

Abstract

Acute myeloid leukemia AML is a heterogeneous hematological malignancy Treatment of patients suffering from highrisk AML as defined by clinical parameters cytogenetics and/or molecular analyses is often unsuccessful OSI461 is a proapoptotic compound that has been proposed as a novel therapeutic option for patients suffering from solid tumors like prostate or colorectal carcinoma But little is known about its antiproliferative potential in AML Hence we treated bone marrow derived CD34+ selected blast cells from 20 AML patients and the five AML cell lines KG1a THP1 HL60 U937 and MV411 with the physiologically achievable concentration of 1 μM OSI461 or equal amounts of DMSO as a control Following incubation with OSI461 we found a consistent induction of apoptosis and an accumulation of cells in the G2/M phase of the cell cycle In addition we demonstrate that the OSI461 mediated antiproliferative effects observed in AML are associated with the induction of the proapoptotic cytokine mda7/IL24 and activation of the growth arrest and DNAdamage inducible genes GADD 45α and 45γ Furthermore OSI461 treated leukemia cells did not regain their proliferative potential for up to 8 days after cessation of treatment following the initial 48 h treatment period with 1 μM OSI461 This indicates sufficient targeting of the leukemiainitiating cells in our in vitro experiments through OSI461 The AML samples tested in this study included samples from patients who were resistant to conventional chemotherapy and/or had FLT3ITD mutations demonstrating the high potential of OSI461 in human AMLAC and IB are supported by grants from Leukämie Liga eV Düsseldorf Germany and the Forschungskommission of the HeinrichHeineUniversity Düsseldorf Germany AC is further supported by the Deutsche Krebshilfe through a Dr Mildred Scheel fellowship award and by a research fellowship award from the European Association of Hematology EHA LFZ is supported by Department of Defense grants PC051217 and OC0060439

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia
  2. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications
  3. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement
  4. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma
  5. Therapeutic implication of BAL in patients with neutropenia
  6. Effect of altered iron metabolism on markers of haem biosynthesis and intestinal iron absorption in mice
  7. Glucose-6-phosphate dehydrogenase deficiency and risk of diabetes: a systematic review and meta-analysis
  8. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation
  9. Lung injury in a leukemia patient during mobilization of peripheral blood stem cells using granulocyte colony-stimulating factor alone
  10. Primary MALT lymphoma of the urinary bladder in the background of interstitial cystitis
  11. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial
  12. Epidemiological profile of hemoglobinopathies in the Mauritanian population
  13. Efficacy and safety of deferasirox in myelodysplastic syndromes
  14. Haemoglobin Hokusetsu [β52 (D3)] Asp→Gly in German families associated with inclusion body
  15. Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML)
  16. Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis
  17. Is the quantity of circulatory cell-free DNA in human plasma and serum samples associated with gender, age and frequency of blood donations?
  18. Searching for antigen epitope specificities in the monoclonal IgG molecules of patients with multiple myeloma. The description of a monoclonal antibody with a dynein-specific antigen epitope character
  19. A de novo ankyrin mutation (ANK1 Q109X) causing severe hereditary spherocytosis from preterm neonatal period
  20. Reusable terminal tap water filters for nosocomial legionellosis prevention
  21. Association between low uric acid levels and acute graft-versus-host disease
  22. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects
  23. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation
  24. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR–ABL-positive acute lymphoblastic leukemia—retrospective analysis of Polish Adult Leukemia Group (PALG)
  25. High-risk AML complicated by pulmonary aspergillosis: successful treatment with nonmyeloablative stem cell transplantation and long-term administration of voriconazole
  26. Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab
  27. Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman’s disease
  28. Perioperative management of a patient with Fechtner syndrome
  29. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia
  30. Long-term results of autologous stem cell transplantation for Hodgkin’s disease (HD) and low-/intermediate-grade B non-Hodgkin’s lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR)
  31. Storage time of red blood cell concentrates and adverse outcomes after cardiac surgery: a cohort study
  32. HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab
  33. Fatal chylous ascites, pericarditis and extensive venous thrombosis, due to an aggressive T cell non-Hodgkin lymphoma
  34. Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome
  35. Clonal relationship in multifocal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue (MALT)
  36. Decrease in circulating percentage platelet microparticles during pregnancy—a different perspective
  37. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information
  38. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases
  39. Chronic immune thrombocytopenic purpura—who needs medication?
  40. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
  41. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting
  42. Maximum standard uptake value of 18 F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma
  43. Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation
  44. FLT3 -ITD and MLL -PTD influence the expression of MDR-1 , MRP-1 , and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia
  45. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors
  46. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
  47. Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements
  48. Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β-thalassemia
  49. Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry
  50. Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry
  51. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
  52. Ciprofloxacin inhibits lipopolysaccharide-induced toll-like receptor-4 and 8 expression on human monocytes derived from adult and cord blood
  53. Constitutional pericentric inversion of chromosome 9 and hematopoietic recovery after allogeneic stem cell transplantation
  54. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes
  55. Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors—results from a Dutch population-based study
  56. Primary cardiac lymphoma mimicking atrial thrombus in a patient who underwent permanent pacemaker implantation
  57. Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma
  58. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia
  59. Therapy-related myelodysplastic syndrome/acute myeloid leukemia M2 and translocation (8;21)
  60. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis
  61. Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation
  62. Concomitant plasmacytoma and B cell lymphoma with discordant light chain expression but clonal identity
  63. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
  64. Demyelination in the brain as a paraneoplastic disorder: candidates include some cases of leukemia and non-Hodgkin's lymphoma
  65. N -acetylcysteine reduces oxidative stress in sickle cell patients
  66. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy
  67. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy
  68. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents
  69. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
  70. Hematologic malignancies with PCM1 - JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA , PDGFRB , and FGFR1
  71. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
  72. Frequency of the hemochromatosis gene ( HFE ) 282C→Y, 63H→D, and 65S→C mutations in a general Mediterranean population from Tarragona, Spain
  73. Focal splenic lesions in myeloproliferative disease: association with fatal outcome
  74. Stenotrophomonas maltophilia septicemia with pyomyositis in a chemotherapy-treated patient
  75. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
  76. Durable complete remission after chemotherapy and rituximab in a case of Waldenström’s macroglobulinemia with pleuropulmonary involvement
  77. Human promoter mutations unveil Oct-1 and GATA-1 opposite action on Gfi1b regulation
  78. Human promoter mutations unveil Oct-1 and GATA-1 opposite action on Gfi1b regulation
  79. Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy
Search Result: